English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12340/13512 (91%)
造訪人次 : 2254931      線上人數 : 229
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13592


    題名: How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers?
    作者: Chen, MH;Lu, SN;Chen, CH;Lin, PC;Jiang, JK;D'Yachkova, Y;Lukanowski, M;Cheng, R;Chen, LT
    貢獻者: National Institute of Cancer Research
    摘要: Simple Summary Malignancies of the gastrointestinal (GI) tract are among the five most common cancers worldwide. Despite significant therapeutic improvements over the last decade, this group of cancers is characterized by high recurrence rates and a dismal prognosis. There is an urgent need for new therapeutic approaches. New blood vessel formation is pivotal to tumor growth. Ramucirumab (Cyramza(R) (Eli Lilly and Company, IN, USA)) is a monoclonal antibody that specifically binds to and blocks the activation of vascular endothelial growth factor (VEGF) receptor 2. Ramucirumab is approved for a number of GI tract malignancies either as monotherapy or in combination with chemotherapies. Here, we give an overview of the survival and tolerability data for ramucirumab from phase 3 randomized controlled clinical trials in GI cancers including those from important pre-specified patient subgroups and evidence from real clinical practice worldwide. Our aim is to summarize these data to demonstrate how ramucirumab may help improve treatment outcome for patients with GI cancers. GI cancers are characterized by high recurrence rates and a dismal prognosis and there is an urgent need for new therapeutic approaches. This is a narrative review designed to provide a summary of the efficacy as measured by overall survival, progression free survival, and safety data from phase 3 randomized controlled GI clinical trials of ramucirumab including those from important pre-specified patient subgroups and evidence from real clinical practice worldwide. Quality of life (QOL) is discussed where data are available. Our aim was to summarize the efficacy and safety of ramucirumab in the treatment of GI cancers using these existing published data with a view to demonstrating how ramucirumab may help improve treatment outcome for patients with GI cancers. The data indicate that ramucirumab is efficacious, safe, and tolerable across the intent-to-treat patient populations as a whole and across several pre-specified subgroups, even those whose disease is traditionally more difficult to treat. Furthermore, survival outcomes observed in real-world clinical practice demonstrate similar data from phase 3 clinical trials even in patients with complications, suggesting that the benefits of ramucirumab translate in actual clinical practice.
    日期: 2021-07-15
    關聯: Cancers. 2021 Jul 15;13(14):Article number 3536.
    Link to: http://dx.doi.org/10.3390/cancers13143536
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2072-6694&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000676186000001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85110217383
    顯示於類別:[陳立宗] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000676186000001.pdf7113KbAdobe PDF235檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋